June 29, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) announces updated potential market for tissue cultured marijuana clone plantlets to be produced at the Cannabis Botany Centre and an update on financing activities.
Alliance Growers is continually updating the potential market for tissue cultured marijuana clone plantlets utilizing published data of the annual plants required by licensed growers. According to recent published data, dedicated grow-out space of the top 50 percent of Licensed ACMPR producers require 7,300,000 plants currently with ongoing expansion to 16,000,000 plants by 2019. The additional 50% of producers should add similar quantities bringing the total to 14,000,000 plants currently and with expansion estimated to be 32,000,000 plants required annually, by 2019. New licenses to be added by July 1st 2018 could push the number even higher to an estimated 22,000,000 plants required annually with expansion plans pushing out to over 40,000,000 marijuana plants to meet market supply.
The Cannabis Botany Centre is expected to produce and sell a minimum of 3,000,000 plantlets annually at a gross profit of $4.00 per plantlet for estimated gross profit of $12,000,000. 3,000,000 plantlets represents approximately 20% of the requirements of the top 50% of Licensed ACMPR producers and approximately 10% if all current Licensed ACMPR producers, including planned expansion. Alliance Growers believes that tissue cultured marijuana clone plantlets will become the standard with Health Canada as we move toward legalization. https://www.newcannabisventures.com/tissue-culture-for-cannabis-cultivation-could-replace-cloning-as-the-gold-standard/.
To fund the Cannabis Botany Centre, Alliance Growers is in negotiations on two avenues of non-dilutive financing. One being the issuance of Class A preferred shares as previously announced and the second with a Streaming company. A German financial institution has notified Alliance Growers that a proposal is being prepared for our review within the coming two weeks.
On June 7, 2017, the Company announced our agreement with a German licensed producer applicant, Plantisaneco Gmbh (“Plantisaneco”), whereby Alliance Growers will earn a significant percentage of the equity in Plantisaneco in return for providing certain services and expertise. On the same day as that announcement, Alliance Growers was approached by a private Streaming Finance Company that provides non-equity financing solutions for cannabis producers. The payments from Alliance Growers to the Streaming company would in a sense, be a form of royalty based on a percentage of production. The discussions include funding the Cannabis Botany Centre as well as the 11,000-square foot production facility in Kelowna, British Columbia the Kelowna, currently under application with Health Canada.
Commenting on the financing options, Dennis Petke, Alliance Growers’ President and CEO commented, “We have been working diligently to provide the most efficient, non-dilutive financing options to fund our projects, especially the Botany Centre. We are extremely pleased to be in discussions with the streaming financing company. We are providing them with updated market potential numbers for their further review to estimate the cash flow potential of Cannabis Botany Centre. The streaming finance company originally approached Alliance Growers about financing the Plantisaneco operation in Germany, as they have already partially financed a grow operation in that country. Alliance Growers continues to build relationships within the investment community simultaneously through private placements, a Class A preferred share offering and now streaming financing. We are getting closer to finding the right combination and the right fit with the various financing sources and expect to full finance all of our projects in the coming months.”.
Plantisaneco is currently a license applicant under the Federal Institute for Drugs and Medical Devices, in the Federal State of Germany. After the newly passed law for the prescription of medical cannabis and the loosening of the regulations that classified those people that are suffering as eligible, the estimated consumer market will grow rapidly to over 800,000 people within the next few years. To fill the demand, the federal agencies are seeking potential growers who will provide an excellent, high quality product. To benefit from the market opening, Plantisaneco is in the application process to obtain approval for growing licenses of up to 1400 KG of medical cannabis annually.
About Alliance Growers
Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.
Alliance Growers has executed an agreement with Botanical Research In Motion International Inc., for a Canada Exclusive License to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.
Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.
If you would like to be added to Alliance Growers’ news distribution list, please send your email address to firstname.lastname@example.org
On behalf of the board of directors of
ALLIANCE GROWERS CORP.
President and CEO
For more information contact:
Corporate Communications Consultant
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.